Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bavarian Nordic announced it could receive up to $975 million including $60 million upfront, plus development, regulatory and commercialization milestones and…
GEN noted the deal size implied potential blockbuster framing for PROSTVAC, leveraging the Phase 2 8.5-month OS signal while acknowledging Phase 3 readout risk.
FierceBiotech reported Bavarian Nordic shares plummeted ~49% after the PROSPECT Phase 3 trial was halted for futility, with PROSTVAC failing to extend overall…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS gained an exclusive option to license PROSTVAC, Bavarian Nordic's Phase 3 PSA-targeting cancer immunotherapy. Bavarian Nordic received $60M upfront, with $80M option exercise plus up to $230M survival-tiered, $110M regulatory, and $495M sales milestones. Phase 3 PROSPECT trial later failed to meet OS endpoint (2017).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Bavarian Nordic A/S (PROSTVAC program) (this deal) | 2015 | $975M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2015 deals · Bristol-Myers Squibb Company deals · Oncology deals